Halliburton Wipes 75% Off Dividend; Board Takes Pay Cut

Halliburton Wipes 75% Off Dividend; Board Takes Pay Cut

Halliburton (HAL) has announced today a 2020 second quarter dividend of $0.045 a share on the company’s common stock payable on June 24, 2020, to shareholders of record at the close of business on June 3, 2020.This translates into a 75% decrease from the previous dividend payout of $0.180 and represents a forward yield of 1.61%.“The decision to set the quarterly dividend at a lower level reflects the current market conditions and uncertainties regarding the depth and duration of this downturn” Halliburton says.At the same time, the company’s board of directors also approved a 20% voluntary reduction to their annual retainer. This follows salary reductions already taken by the members of the executive committee.“Halliburton continues to take measures to strengthen our liquidity and financial resilience under the current circumstances. We implemented a $1 billion action plan to reduce overhead and other costs, lowered capital expenditures roughly 50% from 2019 levels and accelerated...

Luckin Stock Faces Wipeout in Rush to Sell Before Delisting

(Bloomberg) -- Luckin Coffee Inc.’s battered stock faces a renewed wave of selling on Wednesday, after Nasdaq Inc. said it planned to delist the onetime market darling that shocked investors with revelations of accounting fraud last month.The Chinese coffee chain’s shares, which had been suspended since tumbling more than 80% in early April, fell another 33% premarket Wednesday as trading resumed in New York. Luckin announced Nasdaq’s intention to delist the company in a statement on Tuesday, saying shares will remain on the exchange pending the outcome of an appeal hearing.The prospect of delisting is likely to trigger a rush for the exit by Luckin’s remaining shareholders, adding to a long list of challenges for the company as it tries to recover from its disclosure that senior executives fabricated about $310 million in sales. Banks including Credit Suisse Group AG, Morgan Stanley and Goldman Sachs Group Inc. are among those with...

U.S. Futures Extend Gains With European Stocks: Markets Wrap

(Bloomberg) -- U.S. equity futures extended gains on Wednesday and European stocks turned higher as investors weighed positive signals on the outlook for markets against fresh outbreaks of the coronavirus. Treasuries and the dollar dipped.Contracts on the S&P 500 and Nasdaq 100 indexes rose further in the European morning, with traders looking beyond Tuesday’s reports that questioned progress in Moderna Inc.’s coronavirus vaccine. The Stoxx Europe 600 Index erased an early decline as health-care and utility shares turned higher. Benchmarks in Japan and India saw the bulk of gains in a mixed Asian session, with Shanghai and Hong Kong in the red.The euro headed for its fourth session of strengthening versus the dollar. Gilts rose as the U.K. sold bonds at a negative yield for the first time. Crude oil added to its four-day rally.Investors have been whipsawed by conflicting news regarding a possible vaccine for the virus, as many governments...

AstraZeneca-Merck Lynparza Prostate Cancer Treatment Gets FDA Approval

AstraZeneca Plc’s (AZN) and Merck Co.’s (MRK) Lynparza drug has received a green light from the U.S. Food and Drug Administration (FDA) for the treatment of patients with advanced prostate cancer.The FDA approval was awarded following results from a Phase III trial, which found that the Lynparza drug treatment reduced the risk of disease progression or death by 66%.Prostate cancer is the second-most common cancer type in men and despite an increase in the number of available therapies for men suffering from the disease, five-year survival remains low.Lynparza is a first-in-class PARP inhibitor, which is a targeted treatment to potentially block DNA damage response (DDR) pathway deficiencies, such as so-called BRCA mutations to kill cancer cells. It is being tested in a range of tumor types. Regulatory reviews are underway in several jurisdictions for ovarian, breast, pancreatic and prostate cancers.“Today marks the first approval for Lynparza in prostate cancer,” said Dave Fredrickson, Executive VP at...